The pharmaceutical landscape in Grenada is evolving, shifting towards advanced therapeutic solutions for metabolic health. As a premier provider of GLP-1 (Glucagon-like peptide-1) receptor agonists, we bridge the gap between high-tech peptide synthesis and local demand. Our strategic focus on high-purity API (Active Pharmaceutical Ingredient) supply ensures that Grenada's healthcare facilities and research sectors have access to clinical-grade compounds compliant with international pharmacopeia standards.
In the Caribbean context, addressing Type 2 Diabetes and obesity requires robust supply chain integrity. We provide comprehensive technical dossiers to ensure local compliance with regulatory frameworks. Our commitment involves not just supplying products, but providing a holistic technological roadmap including lab-setup advisory and procurement transparency.
We adhere to strict cGMP (Current Good Manufacturing Practice) standards. Every batch of Tirzepatide, Semaglutide, and Retatrutide is tested for 99%+ purity, supported by CoA, HPLC, and MS reports.
We provide end-to-end supply chain support, including FDF (Finished Dosage Form) licensing, technical consultation for formulation, and efficient logistics for tropical climates.
